Avaliação dos pacientes com asma grave do ambulatório de pneumologia do Hospital Universitário de Santa Maria em uso de omalizumabe

Detalhes bibliográficos
Autor(a) principal: Fagundes, Ariovaldo Leal
Data de Publicação: 2022
Tipo de documento: Dissertação
Idioma: por
Título da fonte: Manancial - Repositório Digital da UFSM
dARK ID: ark:/26339/0013000004vf1
Texto Completo: http://repositorio.ufsm.br/handle/1/25978
Resumo: Severe asthma is a complex syndrome and an important global health problem that requires an integrated therapeutic approach. With this in mind, the aim of the present study was to clinically and functionally evaluate adult patients with severe uncontrolled allergic asthma, treated at the pulmonology service of the University Hospital of Santa Maria (HUSM), of the Federal University of Santa Maria (UFSM), by using omalizumab. This is a retrospective, cross-sectional and descriptive study, with data obtained through the analysis of medical records. The sample was obtained from the HUSM/UFSM pulmonology service database. Patients using omalizumab, a humanized anti-IgE monoclonal antibody, indicated in patients with severe uncontrolled allergic asthma, were included in the study, after a systematic review of treatment adherence, correct medication inhalation technique, environmental control and treatment of comorbidities. Clinical, functional, and laboratory data from 13 patients were evaluated at 16, 32, and 54 weeks after starting medication. Such data were correlated with asthma control outcomes, measured by the Asthma Control Test (ACT) and by pulmonary function, analyzing forced expiratory volume in one second (FEV1), measured by spirometry and the number of exacerbations. The average age was 50.6 years (ranging from 31 to 64 years), 12 individuals were female, 1 male, there were no active smokers, and seven were obese. In eight of the subjects, symptoms had already started. ACT averaged 9.4 points at the initial or baseline assessment, increasing to 17 points after 54 weeks, and FEV1 averaged 1.50 liters at initial or baseline assessment and 1.90 liters after 54 weeks. In both cases data showed a significant variation, both from a statistical point of view (p = 0.04 for ACT and p = 0.02 for FEV1) and from a clinical point of view (increase of more than three points in ACT and more than 100 ml on FEV1). It was not possible to assess the number of exacerbations. The study is in agreement with previous findings in the literature regarding the results of the use of omalizumab in patients with severe uncontrolled allergic asthma.
id UFSM_bac2074b2a41d02c3cb759ea22430601
oai_identifier_str oai:repositorio.ufsm.br:1/25978
network_acronym_str UFSM
network_name_str Manancial - Repositório Digital da UFSM
repository_id_str
spelling Avaliação dos pacientes com asma grave do ambulatório de pneumologia do Hospital Universitário de Santa Maria em uso de omalizumabeEvaluation of patients with severe bronchial asthma using omalizumab in the pneumology service of the University Hospital of Santa MariaAsma alérgica graveOmalizumabeImunoglobulina EExacerbaçãoSevere allergic asthmaOmalizumabImmunoglobulin EExacerbationCNPQ::CIENCIAS DA SAUDESevere asthma is a complex syndrome and an important global health problem that requires an integrated therapeutic approach. With this in mind, the aim of the present study was to clinically and functionally evaluate adult patients with severe uncontrolled allergic asthma, treated at the pulmonology service of the University Hospital of Santa Maria (HUSM), of the Federal University of Santa Maria (UFSM), by using omalizumab. This is a retrospective, cross-sectional and descriptive study, with data obtained through the analysis of medical records. The sample was obtained from the HUSM/UFSM pulmonology service database. Patients using omalizumab, a humanized anti-IgE monoclonal antibody, indicated in patients with severe uncontrolled allergic asthma, were included in the study, after a systematic review of treatment adherence, correct medication inhalation technique, environmental control and treatment of comorbidities. Clinical, functional, and laboratory data from 13 patients were evaluated at 16, 32, and 54 weeks after starting medication. Such data were correlated with asthma control outcomes, measured by the Asthma Control Test (ACT) and by pulmonary function, analyzing forced expiratory volume in one second (FEV1), measured by spirometry and the number of exacerbations. The average age was 50.6 years (ranging from 31 to 64 years), 12 individuals were female, 1 male, there were no active smokers, and seven were obese. In eight of the subjects, symptoms had already started. ACT averaged 9.4 points at the initial or baseline assessment, increasing to 17 points after 54 weeks, and FEV1 averaged 1.50 liters at initial or baseline assessment and 1.90 liters after 54 weeks. In both cases data showed a significant variation, both from a statistical point of view (p = 0.04 for ACT and p = 0.02 for FEV1) and from a clinical point of view (increase of more than three points in ACT and more than 100 ml on FEV1). It was not possible to assess the number of exacerbations. The study is in agreement with previous findings in the literature regarding the results of the use of omalizumab in patients with severe uncontrolled allergic asthma.Asma grave é uma síndrome complexa e um importante problema de saúde global que necessita de uma abordagem terapêutica integrada. Tendo isso em vista, o objetivo do presente estudo foi avaliar clínica e funcionalmente os pacientes adultos com asma alérgica grave não controlada, atendidos no serviço de pneumologia do Hospital Universitário de Santa Maria (HUSM), da Universidade Federal de Santa Maria (UFSM), em uso de omalizumabe. Trata-se de um estudo retrospectivo, transversal e descritivo, com dados obtidos por meio da análise dos prontuários médicos. A amostra foi obtida do banco de dados do serviço de pneumologia do HUSM/UFSM. Foram incluídos no estudo os pacientes que utilizavam omalizumabe, um anticorpo monoclonal humanizado anti-IgE, indicado em pacientes com asma alérgica grave não controlada, após revisão sistematizada da aderência ao tratamento, da técnica inalatória correta das medicações, do controle ambiental e do tratamento das comorbidades. Foram avaliados os dados clínicos, funcionais e laboratoriais de 13 pacientes por 16, 32 e 54 semanas após o início da medicação. Tais dados foram correlacionados com os desfechos de controle da asma, medido pelo Asthma Control Test (ACT) e pela função pulmonar, analisando-se o volume expiratório forçado no primeiro segundo (VEF1), medido pela espirometria e pelo número de exacerbações. A idade foi, em média, 50,6 anos (com variação de 31 a 64 anos), 12 indivíduos eram do sexo feminino, 1 do sexo masculino, nenhum era fumante ativo e sete eram obesos. Em oito dos indivíduos, os sintomas haviam iniciado. O ACT foi, em média, 9,4 pontos na avaliação basal ou inicial, aumentando para 17 pontos após 54 semanas, e o VEF1 foi, em média, 1,50 litros na avaliação inicial ou basal e 1,90 litros após 54 semanas. Ambos os dados apresentaram variação significativa, tanto do ponto de vista estatístico (p = 0,04 para o ACT e p = 0,02 para o VEF1), quanto do ponto de vista clínico (aumento de mais de três pontos no ACT e mais de 100 ml no VEF1). Não foi possível avaliar o número de exacerbações. O estudo está de acordo com os achados prévios na literatura sobre os resultados do uso de omalizumabe nos pacientes com asma alérgica grave não controlada.Universidade Federal de Santa MariaBrasilCiências da SaúdeUFSMPrograma de Pós-Graduação em Ciências da SaúdeCentro de Ciências da SaúdeMarchiori, Roseane Cardosohttp://lattes.cnpq.br/4797974118988345Weinmann, Angela Regina MacielHaeffner, Leris Salete BonfantiFagundes, Ariovaldo Leal2022-08-25T16:54:57Z2022-08-25T16:54:57Z2022-07-08info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisapplication/pdfhttp://repositorio.ufsm.br/handle/1/25978ark:/26339/0013000004vf1porAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessreponame:Manancial - Repositório Digital da UFSMinstname:Universidade Federal de Santa Maria (UFSM)instacron:UFSM2022-08-25T16:54:57Zoai:repositorio.ufsm.br:1/25978Biblioteca Digital de Teses e Dissertaçõeshttps://repositorio.ufsm.br/ONGhttps://repositorio.ufsm.br/oai/requestatendimento.sib@ufsm.br||tedebc@gmail.comopendoar:2022-08-25T16:54:57Manancial - Repositório Digital da UFSM - Universidade Federal de Santa Maria (UFSM)false
dc.title.none.fl_str_mv Avaliação dos pacientes com asma grave do ambulatório de pneumologia do Hospital Universitário de Santa Maria em uso de omalizumabe
Evaluation of patients with severe bronchial asthma using omalizumab in the pneumology service of the University Hospital of Santa Maria
title Avaliação dos pacientes com asma grave do ambulatório de pneumologia do Hospital Universitário de Santa Maria em uso de omalizumabe
spellingShingle Avaliação dos pacientes com asma grave do ambulatório de pneumologia do Hospital Universitário de Santa Maria em uso de omalizumabe
Fagundes, Ariovaldo Leal
Asma alérgica grave
Omalizumabe
Imunoglobulina E
Exacerbação
Severe allergic asthma
Omalizumab
Immunoglobulin E
Exacerbation
CNPQ::CIENCIAS DA SAUDE
title_short Avaliação dos pacientes com asma grave do ambulatório de pneumologia do Hospital Universitário de Santa Maria em uso de omalizumabe
title_full Avaliação dos pacientes com asma grave do ambulatório de pneumologia do Hospital Universitário de Santa Maria em uso de omalizumabe
title_fullStr Avaliação dos pacientes com asma grave do ambulatório de pneumologia do Hospital Universitário de Santa Maria em uso de omalizumabe
title_full_unstemmed Avaliação dos pacientes com asma grave do ambulatório de pneumologia do Hospital Universitário de Santa Maria em uso de omalizumabe
title_sort Avaliação dos pacientes com asma grave do ambulatório de pneumologia do Hospital Universitário de Santa Maria em uso de omalizumabe
author Fagundes, Ariovaldo Leal
author_facet Fagundes, Ariovaldo Leal
author_role author
dc.contributor.none.fl_str_mv Marchiori, Roseane Cardoso
http://lattes.cnpq.br/4797974118988345
Weinmann, Angela Regina Maciel
Haeffner, Leris Salete Bonfanti
dc.contributor.author.fl_str_mv Fagundes, Ariovaldo Leal
dc.subject.por.fl_str_mv Asma alérgica grave
Omalizumabe
Imunoglobulina E
Exacerbação
Severe allergic asthma
Omalizumab
Immunoglobulin E
Exacerbation
CNPQ::CIENCIAS DA SAUDE
topic Asma alérgica grave
Omalizumabe
Imunoglobulina E
Exacerbação
Severe allergic asthma
Omalizumab
Immunoglobulin E
Exacerbation
CNPQ::CIENCIAS DA SAUDE
description Severe asthma is a complex syndrome and an important global health problem that requires an integrated therapeutic approach. With this in mind, the aim of the present study was to clinically and functionally evaluate adult patients with severe uncontrolled allergic asthma, treated at the pulmonology service of the University Hospital of Santa Maria (HUSM), of the Federal University of Santa Maria (UFSM), by using omalizumab. This is a retrospective, cross-sectional and descriptive study, with data obtained through the analysis of medical records. The sample was obtained from the HUSM/UFSM pulmonology service database. Patients using omalizumab, a humanized anti-IgE monoclonal antibody, indicated in patients with severe uncontrolled allergic asthma, were included in the study, after a systematic review of treatment adherence, correct medication inhalation technique, environmental control and treatment of comorbidities. Clinical, functional, and laboratory data from 13 patients were evaluated at 16, 32, and 54 weeks after starting medication. Such data were correlated with asthma control outcomes, measured by the Asthma Control Test (ACT) and by pulmonary function, analyzing forced expiratory volume in one second (FEV1), measured by spirometry and the number of exacerbations. The average age was 50.6 years (ranging from 31 to 64 years), 12 individuals were female, 1 male, there were no active smokers, and seven were obese. In eight of the subjects, symptoms had already started. ACT averaged 9.4 points at the initial or baseline assessment, increasing to 17 points after 54 weeks, and FEV1 averaged 1.50 liters at initial or baseline assessment and 1.90 liters after 54 weeks. In both cases data showed a significant variation, both from a statistical point of view (p = 0.04 for ACT and p = 0.02 for FEV1) and from a clinical point of view (increase of more than three points in ACT and more than 100 ml on FEV1). It was not possible to assess the number of exacerbations. The study is in agreement with previous findings in the literature regarding the results of the use of omalizumab in patients with severe uncontrolled allergic asthma.
publishDate 2022
dc.date.none.fl_str_mv 2022-08-25T16:54:57Z
2022-08-25T16:54:57Z
2022-07-08
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/masterThesis
format masterThesis
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://repositorio.ufsm.br/handle/1/25978
dc.identifier.dark.fl_str_mv ark:/26339/0013000004vf1
url http://repositorio.ufsm.br/handle/1/25978
identifier_str_mv ark:/26339/0013000004vf1
dc.language.iso.fl_str_mv por
language por
dc.rights.driver.fl_str_mv Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidade Federal de Santa Maria
Brasil
Ciências da Saúde
UFSM
Programa de Pós-Graduação em Ciências da Saúde
Centro de Ciências da Saúde
publisher.none.fl_str_mv Universidade Federal de Santa Maria
Brasil
Ciências da Saúde
UFSM
Programa de Pós-Graduação em Ciências da Saúde
Centro de Ciências da Saúde
dc.source.none.fl_str_mv reponame:Manancial - Repositório Digital da UFSM
instname:Universidade Federal de Santa Maria (UFSM)
instacron:UFSM
instname_str Universidade Federal de Santa Maria (UFSM)
instacron_str UFSM
institution UFSM
reponame_str Manancial - Repositório Digital da UFSM
collection Manancial - Repositório Digital da UFSM
repository.name.fl_str_mv Manancial - Repositório Digital da UFSM - Universidade Federal de Santa Maria (UFSM)
repository.mail.fl_str_mv atendimento.sib@ufsm.br||tedebc@gmail.com
_version_ 1815172283923169280